替比夫定治疗对慢性乙型肝炎和肝硬化患者血清可溶性红细胞补体受体1的影响

王方; 权作华; 杨兴坤; 寇俊峰; 云升皓; 蔡国芳; 周新人

doi:10.3969/j.issn.1001-5256.2016.06.019

替比夫定治疗对慢性乙型肝炎和肝硬化患者血清可溶性红细胞补体受体1的影响

DOI: 10.3969/j.issn.1001-5256.2016.06.019

1. 兰州军区兰州总医院安宁分院感染科
2. 武威市医院口腔科

详细信息

中图分类号: R512.62;R575.2
计量
- 文章访问数: 1835
- HTML全文浏览量: 9
- PDF下载量: 445
- 被引次数: 0
出版历程
- 出版日期: 2016-06-20

Influence of antiviral therapy with telbivudine on serum soluble complement receptor type 1 in patients with chronic hepatitis B or liver cirrhosis

摘要

摘要: 目的观察慢性乙型肝炎（CHB）和肝硬化患者经替比夫定抗病毒治疗3、6个月后血清可溶性红细胞补体受体1（s CR1）的变化,探讨替比夫定治疗对于s CR1水平的的影响。方法选择2013年1-6月在兰州军区兰州总医院安宁分院就诊的HBe Ag阳性CHB、肝硬化患者57例,给予替比夫定抗病毒治疗,于治疗前和治疗后3、6个月抽静脉血,采用ELISA法检测s CR1。组内比较采用配对t检验。两组间比较采用独立样本t检验。结果替比夫定抗病毒治疗后,全部患者在治疗3、6个月时s CR1与对应的基线水平相比差异有统计学意义（t值分别为4.864、6.238,P值均<0.05）。CHB患者和肝硬化患者s CR1水平在治疗3、6个月时与对应的基线相比差异均有统计学意义（t值分别为3.425、5.468、4.047、7.378,P值均<0.05）。CHB患者血清s CR1水平在基线、治疗3、6个月均较肝硬化患者低,但两组间各时间点相比差异均无统计学意义（P值均>0.05）。结论 HBe Ag阳性CHB、肝硬化患者经替比夫定抗病毒治疗后血清s CR1水平显著下降。
- 肝炎,乙型,慢性 /
- 肝硬化 /
- 替比夫定 /
- 受体,补体
Abstract: Objective To investigate the changes in serum soluble complement receptor type 1(s CR1) at 3 and 6 months after antiviral therapy with telbivudine in patients with chronic hepatitis B(CHB) or liver cirrhosis and the influence of telbivudine on serum s CR1 level.Methods A total of 57 patients with HBe Ag- positive CHB or liver cirrhosis were enrolled and given the antiviral therapy with telbivudine.Venous blood was collected before treatment and at 3 and 6 months after treatment,and enzyme- linked immunosorbent assay was used to measure serum s CR1 level.The paired t- test was used for comparison within one group.Results At 3 and 6 months after the antiviral treatment with telbivudine,the serum s CR1 level changed significantly compared with corresponding baseline values(t = 4.864 and 6.238,both P < 0.05).The patients with CHB or liver cirrhosis showed significant changes in the serum s CR1 level at 3 and 6 months after treatment compared with corresponding baseline values(t = 3.425,5.468,4.047,7.378 all P < 0.05).The patients with CHB had a lower serum s CR1 level at baseline and at 3 and 6 months after treatment than those with liver cirrhosis,but the serum s CR1 level at each time point showed no significant differences between the two groups(all P > 0.05).Conclusion In patients with HBe Ag- positive CHB or liver cirrhosis,serum s CR1 level is reduced significantly after antiviral therapy with telbivudine.
- hepatitis B /
- chronic /
- liver cirrhosis /
- telbifvdine

HTML全文

参考文献(15)

[1]WEBSTER GJ,REIGNAT S,MAINI MK,et al.Incubationphase of acute hepatitis B in man:dynamic of cellularimmune mechanisms[J].Hepatology,2000,32(5):1117-1124.

[2]RAPICETTA M,FERRARI C,LEVRERO M.Viral determinants and host immune responses in the pathogenesis of HBV infection[J].J Med Viro,2002,67(3):454-457.

[3]TANNER MS.Mechanisms of liver injury relevant to pediatric hepatology[J].Crit Rev Clin Lab Sci,2002,39(1):1-61.

[4]MAINI MK,BONI C,LEE CK,et al.The role of virus specific CD8(+)cells in liver damage and viral control during persisten the patitis B virus infection[J].J Exp Med,2000,191(8):1269-1280.

[5]LIAW YF,GANE E,LEUNG N,et al.2 year GLOBE trial results:telbivudine is superior to lamivudine in patiants with chronic hepatitis B[J].Gstroenterology,2009,136(2):486-495.

[6]HOU JL,YIN YK,XU D,et al.A PhaseⅢcomparative trial of telbivudine and lamivudine for treatment of chronic hepatitis B in Chinense patients:first year results[R].Shanghai-Hong Kong international Liver Congress,2006,180.

[7]EVANS A,RIVA A,COOKSLEY H,et al.Programmed death 1 expression during antiviral treatment of chronic hepatitis B:Impact of hepatitis B e-antigen seroconversion[J].Hepatology,2008,48(3):759-769.

[8]ZHANG MJ,ZHOU JJ,FU XL,et al.The effect of telbivudine on peripheral blood CD4+CD25+CD127lowT cells and CD8+CD25+Tcells and its clinical significance[J].Immunol J,2010,26(7):594-597.(in Chinese)张梦军,周吉军,傅晓岚,等.替比夫定对慢性乙型肝炎患者外周血细胞频率的影响及临床意义[J].免疫学杂志,2010,26(7):594-597.

[9]ZHU B,ZHANG P,WANG TB,et al.Measurement of Th1/Th2cytokine levels in chronic hepatitis B during telbivudine therapy[J].J Clin Hepatol,2009,25(6):415-417.(in Chinese)朱斌,张平,王天宝,等.替比夫定治疗慢性乙肝血清Th1/Th2亚群细胞因子的水平变化[J].临床肝胆病杂志,2009,25(6):415-417.

[10]LUO LS,ZHANG JW,ZHOU JL,et al.Distribution and significance of spots mutation of complement receptor type 1 gene of erythrocytes in patients with E antigen positive[J].J Pract Med,2011,27(15):2838-2840.(in Chinese)罗丽莎,张继万,周建丽,等.HBe Ag阳性慢性乙肝患者红细胞补体受体Ⅰ型分子基因点突变的分布及意义[J].实用医学杂志,2011,27(15):2838-2840.

[11]LI XB,YANG WD.Advances in clinical research on immune function of erythrocytes in patients with liver diseases[J].Lab Med Clin,2008,5(2):104-106.(in Chinese)李续斌,杨文东.肝脏疾病患者红细胞免疫功能临床研究进展[J].检验医学与临床,2008,5(2):104-106.

[12]DONG GF,LIU DY,WANG JB,et al.The changes and the significance of soluble complement receptor type 1 in serum of patients with hepatitis B gravis[J].Chin J Hepatol,2004,12(2):108-109.(in Chinese)董格峰,刘典勇,王晶波,等.重型肝炎患者血清可溶性补体受体Ⅰ型的变化及临床意义[J].中华肝脏病杂志,2004,12(2):108-109.

[13]LUO LS,ZHANG JW,ZHOU JL,et el.Relationship between the red cell nature immune adhesion function and the concentrations of the soluble complement receptor type 1 in patients with e antigen positive[J].Lab Med Clin,2012,9(9):1069-1071.(in Chinese)罗丽莎,张继万,周建丽,等.慢性乙型肝炎患者红细胞天然免疫黏附功能与血清s CR1变化的相关性研究[J].检验医学与临床,2012,9(9):1069-1071.

[14] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[15]WANG H,WANG XF,YANG LH,et al.Changes and clinical significance of solub1e complement receptor I(s CR 1)of patients with hepatitis[J].Chin J Heal Lab Tech,2007,17(10):1757-1758.(in Chinese)王晗,王雪飞,杨丽华,等.不同肝病患者血清s CR1浓度变化及临床意义研究[J].中国卫生检验杂志,2007,17(10):1757-1758.

施引文献

资源附件(0)

访问统计